<DOC>
<DOCNO>EP-0612315</DOCNO> 
<TEXT>
<INVENTION-TITLE>
NITRO COMPOUNDS HAVING VASODILATOR ACTIVITY.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3112	A61K3112	A61K31165	A61K31165	A61K3121	A61K31215	A61K3140	A61K3140	A61K31403	A61K31403	A61K31404	A61K3141	A61K3141	A61K31415	A61K31415	A61K314164	A61K314164	A61K3142	A61K3142	A61K31423	A61K31423	A61K31433	A61K31433	A61K3144	A61K3144	A61K314402	A61K314402	A61K314406	A61K314406	A61K314409	A61K314409	A61K314418	A61K314418	A61K3147	A61K3147	A61P700	A61P702	A61P900	A61P908	C07C24900	C07C24906	C07C25100	C07C25140	C07C27100	C07C27112	C07C27500	C07C27520	C07C30700	C07C30706	C07C31100	C07C31105	C07C31900	C07C31920	C07C32300	C07C32323	C07D20900	C07D20934	C07D20938	C07D20948	C07D21300	C07D21356	C07D21371	C07D21378	C07D21380	C07D21381	C07D21382	C07D21500	C07D21554	C07D23100	C07D23114	C07D23300	C07D23384	C07D23390	C07D23392	C07D23900	C07D23938	C07D24100	C07D24114	C07D24124	C07D24900	C07D24910	C07D25300	C07D25300	C07D25700	C07D25704	C07D26100	C07D26118	C07D27700	C07D27756	C07D27770	C07D27774	C07D28500	C07D28512	C07D285125	C07D47100	C07D47104	C07D47300	C07D47338	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P7	A61P7	A61P9	A61P9	C07C249	C07C249	C07C251	C07C251	C07C271	C07C271	C07C275	C07C275	C07C307	C07C307	C07C311	C07C311	C07C319	C07C319	C07C323	C07C323	C07D209	C07D209	C07D209	C07D209	C07D213	C07D213	C07D213	C07D213	C07D213	C07D213	C07D213	C07D215	C07D215	C07D231	C07D231	C07D233	C07D233	C07D233	C07D233	C07D239	C07D239	C07D241	C07D241	C07D241	C07D249	C07D249	C07D253	C07D253	C07D257	C07D257	C07D261	C07D261	C07D277	C07D277	C07D277	C07D277	C07D285	C07D285	C07D285	C07D471	C07D471	C07D473	C07D473	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A few nitro compound of formula (I), wherein R
<
1
>
 and R
<
2
>
 are each lower alkyl or lower alkoxy(lower)-alkyl, or (a) is cyclized to form (b), X is -O-, -S- or -NH-, m is an integer 0 or 1, and R
<
3
>
 is carbamoyl, lower alkylcarbamoyl, lower alkanoyl, di-lower alkylaminosulfonyl, lower alkylsulfonyl, oxamoyl or a group of the formula: -(Y)n-R
<
4
>
, wherein Y is -CO-, -SO2-, -COCH2 or (c), n is an integer of 0 or 1, and R
<
4
>
 is heterocyclic group which is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, phenyl, carbamoyl, halogen, amino, lower alkylthio, hydroxy, lower alkylsulfonylamino and carbamoylmethyl, and pharmaceutically acceptable salt thereof, which are useful for vasodilator.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
 DESCRIPTIONTITLE OF INVENTION NITRO COMPOUNDS HAVING VASODILATOR ACTIVITYTECHNICAL FIELDThis invention relates to new nitro compounds. More particularly, this invention relates to new nitro compounds and their pharmaceutically acceptable salts, which are useful for vasodilator, to processes for preparation thereof, to a pharmaceutical composition comprising the same and to a method of use thereof.BACKGROUND ARTEP-A-0113106 discloses nitro compounds which are useful for vasodilator, but an increase of durability of pharmacological effect of these compounds is desired. This invention is to provide new nitro compounds which are useful for vasodilator and have increased durability of pharmacological effect.DISCLOSURE OF INVENTIONThe objective new nitro compounds are represented by the following formula (I) :
 - ~ -wherein R 1 and R2 are e r)-alkyl, or 
X is -0-, -S- or -NH-, m is an integer 0 or 1, andR is carbamoyl, lower alkylcarbamoyl, lower alkanoyl, di-lower alkylaminosulfonyl, lower alkylsulfonyl,4 oxamoyl or a group of the formula : -(Y)n-RNCN II wherein Y is -CO-, -SO--, -COCH^- or -C-, n is an integer of 0 or 1, andR is heterocyclic group which is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, phenyl, carbamoyl, halogen, amino, lower alkylthio, hydroxy, lower alkylsulfonylamino and carbamoylmethyl.Preferred examples and illustrations of various definitions in the description hereinabove and hereinbelow, which the present invention includes within the scope thereof are explained in detail as follows.The term "lower" is intended to mean 1 to 6 carbon atoms, unless otherwise indicated.Preferred example of "lower alkyl" may include a residue of straight and branched alkane having 1 to 6 carbon atom(s) such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl and the like.Preferred examples of "lower alkylcarbamoyl" may include methylcarbamoyl, N,N-dimethylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, isopropylcarbamoyl, butylcarbamoyl, isobutylcarbamoyl, tert-butylcarbamoyl and 

 the like.Preferred examples of "lower alkanoyl" may include formyl, acetyl, propionyl, butyl, isobutyryl, valeryl,4* isovaleryl, pivaloyl, hexanoyl, 3,3-dimethylbutyryl and4 5 the like.Preferred examples of "di-lower alkylaminosulfonyl" may include di-methylaminosulfonyl, di-ethylaminosulfonyl and the like.Preferred examples of "halogen" is fluorine, 10 chlorine, bromine and iodine.Preferred examples of "lower alkoxy" may
</DESCRIPTION>
<CLAIMS>
 C L A I S
1. A compound of the formula :

 wherein R 1 and R2 are each lower alkyl or lower alkoxy(lower)alkyl,
or 

X iε -0-, -S- or -NH-, m iε an integer 0 or 1, and 3
R lε carbamoyl, lower alkylcarbamoyl, lower alkanoyl, di-lower alkylaminoεulfonyl, lower alkylεulfonyl, oxamoyl or a group of the formula : -(Y)
n
~R
4
NCN wherein Y iε -CO-, -S0
2
~, -C0CH
2
~ or -C-, n iε an integer of 0 or 1, and
4 R iε heterocyclic group which iε optionally substituted with one or more subεtituentε εelected from lower alkyl, lower alkoxy, phenyl, carbamoyl, halogen, amino, lower alkylthio, hydroxy, lower alkylεulfonylamino and carbamoylmethyl, and pharmaceutically acceptable εalt thereof.
A proceεε for preparing a compound of the following formula or itε εalt :
N0 ' NOH R
1
-CH-C=CH-C-CH 2
0
-(X) -R
3

 which comprises reacting a compound of the following formula or its salt :
with dinitrogen trioxide, or in the presence of an acid, a nitrite.
10 In the above formulas, R 1 and R2 are each lower alkyl or lower alkoxy(lower)alkyl,
5
 or


 is cyclized to form 

X is -0-, -S- or -NH-, m iε an integer 0 or 1, and
3 R is carbamoyl, lower alkylcarbamoyl, lower alkanoyl, di-lower alkylaminosulfonyl, lower 0 alkylsulfonyl, oxamoyl or a group of the formula : -(Y)
n
-R
4
NCN II wherein Y is -CO-, -SO--, -COCH-- or -C-, 5 n is an integer of 0 or 1, and
4 R is heterocyclic group which is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, phenyl, carbamoyl, halogen, amino, 
Q
 lower alkylthio, hydroxy, lower alkylεulfonylamino and carbamoylmethyl.
3. A vasodilative composition comprising, as an effective ingredient, a compound of the formula : 

wherein R 1 and R2 are each lower alkyl or lower alkoxy(lower)alkyl,
or 

X iε -0-, -S- or -NH-, m iε an integer 0 or 1, and
3 R lε carbamoyl, lower alkylcarbamoyl, lower alkanoyl, di-lower alkylaminoεulfonyl, lower alkylεulfonyl, oxamoyl or a group of the formula : -(Y)
n
"R
4
NCN wherein Y is -CO-, -SO--, -C0CH
2
~ or -C-, n is an integer of 0 or 1, and
4 R is heterocyclic group which is optionally subεtituted with one or more εubstituents selected from lower alkyl, lower alkoxy, phenyl, carbamoyl, halogen, amino, lower alkylthio, hydroxy, lower alkylεulfonylamino and carba oylmethyl, or pharmaceutically acceptable εalt thereof.
4. A pharmaceutical compoεition for treatment of angina pectoriε compriεing, aε an effective ingredient, a compound of the formula :

 wherein
1 and R2 are each lower alkyl or lower alkox (lower)alkyl,
or 

X is -O-, -S- or -NH-, m is an integer 0 or 1, and
3 R is carbamoyl, lower alkylcarbamoyl, lower alkanoyl, di-lower alkylaminosulfonyl, lower alkylsulfonyl, oxamoyl or a group of the formula : -(Y)
n
~R
4
NCN wherein Y is -CO-, -S0
2
~, -COCH
2
~ or -C-, n is an integer of 0 or 1, and
4 is heterocyclic group which is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, phenyl, carbamoyl, halogen, amino, lower alkylthio, hydroxy, lower alkylsulfonylamino and carbamoylmethyl, or pharmaceutically acceptable salt thereof. 

</CLAIMS>
</TEXT>
</DOC>
